Research letters

Abdel-Fattah, Mohammed; Meligy, Bassant; Sayed, Riham El; El-Naga, Yosra A

doi:10.1007/s13312-015-0723-x

Cited by 7 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Alcoba et al has concluded that this biomarker cannot distinguish complicated from uncomplicated CAP cases ( p = 0.95) [53], whereas Abdel-Fattah et al have reported that significantly higher median serum CoPEP levels ( p = 0.03) in children with CAP than in healthy controls and in those who died ( p = 0.04) [54], thus supporting the use of this biomarker for identifying children with a potential poor outcome. Finally, in Mycoplasma pneumoniae CAP, lactate dehydrogenase (LDH) has been found to be a good predictor of refractory infection [54]. ROC curve analysis has indicated an AUC of LDH of 0.718 with a cut-off of 379 IU/L, a value higher than that of ESR with a cut-off of 32.5 mm/h.…”

Section: Evaluation Of the Severity Of Pediatric Capmentioning

confidence: 99%

Biomarkers in Pediatric Community-Acquired Pneumonia

Principi

Esposito

2017

IJMS

View full text Add to dashboard Cite

Community-acquired pneumonia (CAP) is an infectious disease caused by bacteria, viruses, or a combination of these infectious agents. The severity of the clinical manifestations of CAP varies significantly. Consequently, both the differentiation of viral from bacterial CAP cases and the accurate assessment and prediction of disease severity are critical for effectively managing individuals with CAP. To solve questionable cases, several biomarkers indicating the etiology and severity of CAP have been studied. Unfortunately, only a few studies have examined the roles of these biomarkers in pediatric practice. The main aim of this paper is to detail current knowledge regarding the use of biomarkers to diagnose and treat CAP in children, analyzing the most recently published relevant studies. Despite several attempts, the etiologic diagnosis of pediatric CAP and the estimation of the potential outcome remain unsolved problems in most cases. Among traditional biomarkers, procalcitonin (PCT) appears to be the most effective for both selecting bacterial cases and evaluating the severity. However, a precise cut-off separating bacterial from viral and mild from severe cases has not been defined. The three-host protein assay based on C-reactive protein (CRP), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), plasma interferon-γ protein-10 (IP-10), and micro-array-based whole genome expression arrays might offer more advantages in comparison with former biomarkers. However, further studies are needed before the routine use of those presently in development can be recommended.

show abstract

Section: Evaluation Of the Severity Of Pediatric Capmentioning

confidence: 99%

Biomarkers in Pediatric Community-Acquired Pneumonia

Principi

Esposito

2017

IJMS

View full text Add to dashboard Cite

show abstract

“…Also, the prognostic power of Copeptin was less than RDW and Pro ADM. In contrast tour results, Abdel-Fattah et al’s review [ 17 ] suggests that Copeptin could be a promising prognostic marker in CAP.…”

Section: Discussionmentioning

confidence: 86%

Red cell distribution width as a prognostic marker for complications of community-acquired pneumonia in children: a comparison with Proadrenomedullin and Copeptin

Moustafa,

Moness,

Ali

2023

BMC Pulm Med

View full text Add to dashboard Cite

Background Community-acquired pneumonia (CAP) is the most common leading cause of morbidity and mortality in children; so, early identification of patients with CAP, who are at risk of complications or high mortality, is very critical to identify patients who need early admission to the intensive care unit. Purpose of the study To explore the prognostic value of Red Cell Distribution Width (RDW), Proadrenomedullin and Copeptin in the prediction of complicated CAP in children. Methods 99 children were enrolled in the study, which was done at the Pediatric Department of Minia University Hospital. Measurement of serum Proadrenomedullin, Copeptin, and RDW was done to all participating children in the first 24 h of admission. Assessment of the severity of CAP was done using the Pediatric Respiratory Severity Score (PRESS). Results The values of RDW, Proadrenomedullin, and Copeptin were significantly higher in the complicated CAP group than in the uncomplicated one (P value < 0.01). There were significant positive correlations between RDW and Proadrenomedullin with PRESS (r 0.56 for both). For the prediction of complications, RDW at cutoff point > 17.4, has 77.7% of sensitivity and 98.6% of specificity, followed by Pro ADM at cutoff point > 5.1 nmol/L, of 74% of sensitivity and 90.2% of specificity. For the prediction of mortality, RDW at cutoff point > 17.4 has 81.25% of sensitivity and 89.16% of specificity. Conclusion The RDW is a reliable predictor of poor outcomes in pediatric CAP.

show abstract

“…The first copeptin assay was a chemiluminescence sandwich immunoassay with coated tubes, developed in 2006 by Brahms GmbH, Hennigsdorf/Berlin, Germany 1 and validated using healthy volunteers and severely ill patients with sepsis 1 . Over the past years, additional copeptin assays have been developed such as the automated KRYPTOR 18 , 19 and various ELISA 20 – 22 tests. Consequently, there are now several commercial assays increasingly being used but a systematic correlation of these different assays has not yet been performed.…”

Section: Discussionmentioning

confidence: 99%

Validity of different copeptin assays in the differential diagnosis of the polyuria-polydipsia syndrome

Sailer

Refardt

Blum

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The aim of this study was to correlate three commercially available copeptin assays and their diagnostic accuracy in the differential diagnosis of the polyuria-polydipsia syndrome. Analyzed data include repeated copeptin measures of 8 healthy volunteers and 40 patients with polyuria-polydipsia syndrome undergoing osmotic stimulation and of 40 patients hospitalized with pneumonia. Copeptin was measured using the automated Brahms KRYPTOR, the manual Brahms LIA and the manual Cloud Clone ELISA assay. Primary outcome was the interrater correlation coefficient (ICC) and diagnostic accuracy in the polyuria-polydipsia syndrome of the three assays. In healthy volunteers, there was a moderate correlation for the KRYPTOR and LIA (ICC 0.74; 95% CI 0.07 to 0.91), and a poor correlation for the KRYPTOR and ELISA (ICC 0.07; 95% CI − 0.06 to 0.29), as for the LIA and ELISA (ICC 0.04; 95% CI − 0.04 to 0.17). The KRYPTOR had the highest diagnostic accuracy (98% (95% CI 83 to100)), comparable to the LIA (88% (95% CI 74 to 100)), while the ELISA had a poor diagnostic accuracy (55% (95% CI 34 to 68)) in the differential diagnosis of the polyuria-polydipsia syndrome. The KRYPTOR and LIA yield comparable copeptin concentrations and high diagnostic accuracy, while the ELISA correlates poorly with the other two assays and shows a poor diagnostic accuracy for polyuria-polydipsia patients. The current copeptin cut-off is valid for the KRYPTOR and LIA assay. Our results indicate that interpretation with other assays should be performed with caution and separate validation studies are required before their use in differentiating patients with polyuria-polydipsia syndrome.Trial registration: NCT02647736 January 6, 2016/NCT01940614 September 12, 2013/NCT00973154 September 9, 2009.

show abstract

Research letters

Cited by 7 publications

References 8 publications

Biomarkers in Pediatric Community-Acquired Pneumonia

Biomarkers in Pediatric Community-Acquired Pneumonia

Red cell distribution width as a prognostic marker for complications of community-acquired pneumonia in children: a comparison with Proadrenomedullin and Copeptin

Validity of different copeptin assays in the differential diagnosis of the polyuria-polydipsia syndrome

Contact Info

Product

Resources

About